Harmony Biosciences Holdings, Inc. (HRMY) Balance Sheet
HRMY balance sheet, 2025
December 31, 2025 · U.S. dollars$1.27B assets = $401.4M liabilities + $870.2M equity
Both columns are drawn to the same scale: what HRMY owns equals what it owes plus shareholders’ equity. Hover a block for its value.
HRMY financial health
Descriptive bands, not a rating. Fiscal 2025.
HRMY balance sheet trends, 2018–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $89.3M2018 | $1.27B2025 | +46.2%/yr | |
| Total liabilities | $7.8M2018 | $401.4M2025 | +75.7%/yr | |
| Shareholders’ equity | $81.5M2018 | $870.2M2025 | +40.3%/yr | |
| Cash & short-term investments | $83.5M2018 | $775.3M2025 | +37.5%/yr | |
| Total debt | $324.2M2018 | $239.6M2025 | −4.2%/yr | |
| Net cash (debt) | −$240.7M2018 | $535.8M2025 | +$776.4M | |
| Working capital | $79.5M2018 | $654.9M2025 | +$575.4M | |
| Book value per share | $1.662018 | $14.862025 | +36.8%/yr | |
| Current ratio | 11.992018 | 3.602025 | −8.39 | |
| Debt / equity | 3.982018 | 0.282025 | −3.70 | |
| Shares outstanding | 49.2M2018 | 58.5M2025 | +2.5%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
HRMY assets
HRMY liabilities and equity
HRMY debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
HRMY balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & short-term investments | $775.3M | $467.2M | $353.5M | $323.1M | $234.3M | $228.6M | $24.5M | $83.5M |
| Cash & equivalents | $752.5M | $453.0M | $311.7M | $243.8M | $234.3M | $228.6M | $24.5M | $83.5M |
| Short-term investments | $22.8M | $14.2M | $41.8M | $79.3M | $0 | — | — | — |
| Receivables | $96.8M | $83.0M | $74.1M | $54.7M | $34.8M | $22.2M | $4.3M | $0 |
| Inventory | $5.4M | $7.2M | $5.4M | $4.3M | $4.4M | $3.8M | $1.1M | $0 |
| Other current assets | $29.5M | $21.8M | $18.1M | $18.1M | $10.9M | $8.3M | $1.7M | $3.2M |
| Total current assets | $907.0M | $579.3M | $451.1M | $400.3M | $284.4M | $262.9M | $31.5M | $86.7M |
| Property, plant & equipment (net) | $5.3M | $3.4M | $371,000 | $573,000 | $4.1M | $938,000 | $1.3M | $1.6M |
| Goodwill & intangible assets | $89.4M | $113.3M | $137.1M | $161.0M | $143.9M | $162.3M | $72.2M | $0 |
| Long-term investments | $107.1M | $108.9M | $72.2M | $22.6M | $0 | $0 | $0 | $0 |
| Other non-current assets | $162.7M | $194.4M | $150.7M | $89.5M | $967,000 | $902,000 | $1.7M | $1.0M |
| Total assets | $1.27B | $999.2M | $811.4M | $673.9M | $433.4M | $427.1M | $106.7M | $89.3M |
| Liabilities | ||||||||
| Accounts payable | $17.7M | $13.7M | $17.7M | $3.8M | $1.0M | $2.6M | $6.4M | $1.5M |
| Short-term debt | $86.9M | $17.6M | $15.0M | $2.0M | $3.4M | — | — | — |
| Deferred revenue | — | — | $123.2M | — | $49.4M | — | — | — |
| Total current liabilities | $252.1M | $175.1M | $163.8M | $78.9M | $53.8M | $134.5M | $19.9M | $7.2M |
| Long-term debt | $143.7M | $163.0M | $178.6M | $189.6M | $190.0M | $194.2M | $97.9M | $0 |
| Other long-term liabilities | $5.6M | $1.9M | $2.1M | $2.5M | $3.2M | $1.1M | $450,000 | $523,000 |
| Total liabilities | $401.4M | $340.0M | $344.5M | $271.0M | $246.9M | $329.9M | $118.3M | $7.8M |
| Shareholders' equity | ||||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Retained earnings (deficit) | $160.9M | $2.2M | −$143.3M | −$272.1M | −$453.6M | −$488.2M | −$422.9M | −$242.7M |
| Accumulated other comprehensive income | $346,000 | $66,000 | $2,000 | −$151,000 | $0 | $0 | −$2,000 | −$2,000 |
| Total shareholders' equity | $870.2M | $659.2M | $467.0M | $402.8M | $186.5M | $97.2M | −$11.6M | $81.5M |
| Key figures | ||||||||
| Total debt | $239.6M | $181.4M | $193.6M | $191.6M | $195.7M | $194.2M | $97.9M | $324.2M |
| Net cash (debt) | $535.8M | $285.8M | $159.9M | $131.5M | $38.6M | $34.4M | −$73.5M | −$240.7M |
| Working capital | $654.9M | $404.2M | $287.3M | $321.4M | $230.7M | $128.4M | $11.6M | $79.5M |
| Tangible book value | $780.8M | $545.9M | $329.9M | $241.9M | $42.6M | −$65.2M | −$83.8M | $81.5M |
| Book value per share | $14.86 | $11.39 | $7.74 | $6.59 | $3.15 | $1.68 | −$0.18 | $1.66 |
| Shares outstanding | 58.5M | 57.9M | 60.4M | 61.1M | 59.2M | 57.8M | 63.7M | 49.2M |
| Current ratio | 3.60 | 3.31 | 2.75 | 5.07 | 5.29 | 1.95 | 1.58 | 11.99 |
| Quick ratio | 3.46 | 3.14 | 2.61 | 4.79 | 5.01 | 1.86 | 1.44 | 11.55 |
| Debt / equity | 0.28 | 0.28 | 0.41 | 0.48 | 1.05 | 2.00 | — | 3.98 |
| Equity / assets | 68.4% | 66.0% | 57.6% | 59.8% | 43.0% | 22.8% | −10.9% | 91.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $667.8M | $640.9M | $775.3M | $672.6M | $565.3M | $507.0M | $467.2M | $410.5M | $346.9M | $372.4M | $353.5M | $370.7M |
| Cash & equivalents | $549.8M | $589.4M | $752.5M | $647.0M | $546.0M | $489.0M | $453.0M | $387.4M | $317.3M | $333.0M | $311.7M | $324.6M |
| Short-term investments | $118.0M | $51.5M | $22.8M | $25.6M | $19.2M | $18.0M | $14.2M | $23.1M | $29.6M | $39.4M | $41.8M | $46.1M |
| Receivables | $111.0M | $108.2M | $96.8M | $100.7M | $93.0M | $106.0M | $83.0M | $81.5M | $83.2M | $79.7M | $74.1M | $67.3M |
| Inventory | $6.4M | $5.3M | $5.4M | $6.9M | $6.1M | $6.4M | $7.2M | $6.9M | $5.6M | $5.9M | $5.4M | $5.1M |
| Other current assets | $29.2M | $24.4M | $29.5M | $58.7M | $27.0M | $23.4M | $21.8M | $23.5M | $22.6M | $21.6M | $18.1M | $20.0M |
| Total current assets | $814.3M | $778.8M | $907.0M | $838.8M | $691.4M | $642.7M | $579.3M | $522.4M | $458.3M | $479.5M | $451.1M | $463.0M |
| Property, plant & equipment (net) | $0 | $5.4M | $5.3M | $2.7M | $2.7M | $3.1M | $3.4M | $3.1M | $3.3M | $3.3M | $2.7M | $2.9M |
| Goodwill & intangible assets | $77.5M | $83.5M | $89.4M | $95.4M | $101.3M | $107.3M | $113.3M | $119.2M | $125.2M | $131.1M | $137.1M | $143.1M |
| Long-term investments | $294.7M | $229.6M | $107.1M | $105.8M | $107.0M | $103.2M | $108.9M | $94.2M | $87.2M | $81.2M | $72.2M | $67.7M |
| Other non-current assets | $186.6M | $174.6M | $162.7M | $165.5M | $205.7M | $199.2M | $194.4M | $189.2M | $184.4M | $151.8M | $148.4M | $101.1M |
| Total assets | $1.37B | $1.27B | $1.27B | $1.21B | $1.11B | $1.06B | $999.2M | $928.1M | $858.4M | $847.0M | $811.4M | $777.8M |
| Liabilities | ||||||||||||
| Accounts payable | $21.7M | $28.6M | $17.7M | $26.3M | $28.3M | $17.5M | $13.7M | $10.5M | $22.7M | $15.1M | $17.7M | $6.5M |
| Short-term debt | $20.0M | $63.2M | $86.9M | $20.8M | $19.6M | $18.6M | $17.6M | $16.5M | $16.8M | $16.8M | $16.4M | $16.7M |
| Deferred revenue | — | — | — | — | — | — | — | −$10.5M | — | — | $123.2M | $83.1M |
| Total current liabilities | $234.1M | $217.3M | $252.1M | $223.4M | $180.1M | $175.1M | $175.1M | $161.3M | $146.6M | $154.3M | $163.8M | $112.4M |
| Long-term debt | $134.0M | $138.8M | $143.7M | $148.5M | $153.3M | $158.2M | $163.0M | $167.8M | $171.4M | $175.0M | $178.6M | $182.1M |
| Other long-term liabilities | $5.8M | $5.3M | $5.6M | $1.2M | $1.4M | $1.7M | $1.9M | $2.2M | $1.8M | $2.3M | $2.1M | $1.9M |
| Total liabilities | $373.8M | $361.5M | $401.4M | $373.1M | $334.9M | $335.0M | $340.0M | $331.3M | $319.8M | $331.6M | $344.5M | $296.4M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Retained earnings (deficit) | $268.8M | $193.4M | $160.9M | $138.4M | $87.6M | $47.8M | $2.2M | −$47.3M | −$93.4M | −$104.9M | −$143.3M | −$169.9M |
| Accumulated other comprehensive income | −$727,000 | −$413,000 | $346,000 | $357,000 | $239,000 | $244,999 | $66,000 | $499,000 | −$234,000 | −$170,999 | $2,000 | −$515,999 |
| Total shareholders' equity | $999.2M | $910.3M | $870.2M | $835.1M | $773.1M | $720.5M | $659.2M | $596.8M | $538.6M | $515.4M | $467.0M | $481.3M |
| Key figures | ||||||||||||
| Total debt | $154.0M | $206.5M | $239.6M | $169.7M | $173.4M | $177.5M | $181.4M | $185.2M | $189.1M | $193.1M | $196.1M | $199.7M |
| Net cash (debt) | $513.8M | $434.4M | $535.8M | $502.8M | $391.9M | $329.5M | $285.8M | $225.2M | $157.8M | $179.3M | $157.4M | $171.0M |
| Working capital | $580.3M | $561.5M | $654.9M | $615.4M | $511.2M | $467.6M | $404.2M | $361.1M | $311.8M | $325.2M | $287.3M | $350.6M |
| Tangible book value | $921.7M | $826.9M | $780.8M | $739.7M | $671.7M | $613.2M | $545.9M | $477.6M | $413.4M | $384.2M | $329.9M | $338.3M |
| Book value per share | $17.00 | $15.49 | $14.83 | $14.22 | $13.23 | $12.31 | $11.32 | $10.27 | $9.36 | $8.95 | $7.93 | $7.93 |
| Shares outstanding | 58.8M | 58.8M | 58.7M | 58.7M | 58.4M | 58.5M | 58.2M | 58.1M | 57.5M | 57.6M | 58.9M | 60.7M |
| Current ratio | 3.48 | 3.58 | 3.60 | 3.75 | 3.84 | 3.67 | 3.31 | 3.24 | 3.13 | 3.11 | 2.75 | 4.12 |
| Quick ratio | 3.33 | 3.45 | 3.46 | 3.46 | 3.65 | 3.50 | 3.14 | 3.05 | 2.93 | 2.93 | 2.61 | 3.90 |
| Debt / equity | 0.15 | 0.23 | 0.28 | 0.20 | 0.22 | 0.25 | 0.28 | 0.31 | 0.35 | 0.37 | 0.42 | 0.41 |
| Equity / assets | 72.8% | 71.6% | 68.4% | 69.1% | 69.8% | 68.3% | 66.0% | 64.3% | 62.7% | 60.9% | 57.6% | 61.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 24, 2026); data from EODHD.
HRMY financial position
At the end of fiscal 2025 (December 31, 2025), Harmony Biosciences had total assets of $1.3 billion (up 27.3% from a year earlier), total liabilities of $401.4 million and shareholders' equity of $870.2 million. It held $775.3 million in cash and short-term investments against $239.6 million of debt, a net cash position of $535.8 million. Its current ratio was 3.60. In the latest quarter (ended June 30, 2026) total assets were $1.4 billion and equity $999.2 million.
Related: HRMY income statement, HRMY cash flow statement, HRMY key metrics. See the HRMY stock overview for the latest quote and news.
HRMY balance sheet FAQ
What are Harmony Biosciences's total assets?
Harmony Biosciences reported total assets of $1.3 billion at the end of fiscal 2025 (December 31, 2025), compared with $999.2 million a year earlier.
How much debt does Harmony Biosciences have?
Harmony Biosciences had $239.6 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was 0.28.
How much cash does Harmony Biosciences have?
Harmony Biosciences held $775.3 million in cash and short-term investments at the end of fiscal 2025; with $239.6 million of debt that is net cash of $535.8 million.
What is Harmony Biosciences's book value?
Harmony Biosciences's shareholders' equity (book value) was $870.2 million at the end of fiscal 2025, or $14.86 per share.
What is Harmony Biosciences's current ratio?
Harmony Biosciences had current assets of $907.0 million and current liabilities of $252.1 million, a current ratio of 3.60 (it can cover its short-term obligations).
How much goodwill does Harmony Biosciences have?
Harmony Biosciences carried $89.4 million of goodwill and intangible assets, 7.0% of total assets, at the end of fiscal 2025.